Power3 discovers biomarkers for early detection of breast cancer
Scientists at Power3 believe that they will be able to make this diagnosis by monitoring the blood serum concentrations of these proteins and then subjecting the results to
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.